 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...192193194195196197198199200201202203204» |
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: PIONEER II: Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Aug 25, 2013
P3, N=300, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: ROCKIES: Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab (clinicaltrials.gov) - Aug 21, 2013
P4, N=250, Recruiting, Sponsor: Amgen
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Combination therapy: REACT2: Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy (clinicaltrials.gov) - Aug 20, 2013
P4, N=1200, Enrolling by invitation, Sponsor: University of Western Ontario, Canada
Recruiting --> Active, not recruiting N=120 --> 1200
- | Humira (adalimumab) / AbbVie
Trial initiation date: Efficacy of Humira in Behcet Patients With Arthritis (clinicaltrials.gov) - Aug 19, 2013
P3, N=15, Recruiting, Sponsor: Rambam Health Care Campus
N=120 --> 1200 Initiation date: Sep 2012 --> Jul 2013
- | Humira (adalimumab) / AbbVie
Enrollment open: Efficacy of Humira in Behcet Patients With Arthritis (clinicaltrials.gov) - Aug 19, 2013
P3, N=15, Recruiting, Sponsor: Rambam Health Care Campus
Initiation date: Sep 2012 --> Jul 2013 Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 15, 2013
P=N/A, N=305, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Humira (adalimumab) / Eisai, AbbVie
New P3 trial, Immune cell: High dose vitamin D treatment in Crohn's disease affects the gut immune cells (EUDRACT) - Jul 31, 2013
P3, N=40, Ongoing, Sponsor: Jørgen Agnholt
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
New P4 trial: A randomized clinical trial: treatment of perianal fistulas in Crohn's disease (EUDRACT) - Jul 24, 2013
P4, N=126, Ongoing, Sponsor: Academic Medical Center
- || Humira (adalimumab) / Eisai, AbbVie
Trial completion: A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease (clinicaltrials.gov) - Jul 24, 2013
P3, N=20, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis (clinicaltrials.gov) - Jul 23, 2013
P3, N=800, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice (clinicaltrials.gov) - Jul 22, 2013
P=N/A, N=505, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Study of Adalimumab in Patients With Axial Spondyloarthritis (clinicaltrials.gov) - Jul 21, 2013
P3, N=192, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | GSK2800528 / GSK
New P1 trial: A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. (clinicaltrials.gov) - Jul 11, 2013
P1, N=45, Active, not recruiting, Sponsor: GlaxoSmithKline
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (clinicaltrials.gov) - Jul 8, 2013
P4, N=110, Recruiting, Sponsor: University Hospital, Tours
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease (clinicaltrials.gov) - Jul 7, 2013
P4, N=60, Recruiting, Sponsor: University of California, San Francisco
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease (clinicaltrials.gov) - Jul 7, 2013
P4, N=60, Recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (clinicaltrials.gov) - Jul 4, 2013
P4, N=110, Recruiting, Sponsor: University Hospital, Tours
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Observational data: SPACTIVE: Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium (clinicaltrials.gov) - Jun 24, 2013
P=N/A, N=200, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Humira (adalimumab) / AbbVie
Trial initiation date, HEOR: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (clinicaltrials.gov) - Jun 24, 2013
P3, N=455, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Initiation date: Feb 2012 --> May 2012
- ||||| Humira (adalimumab) / AbbVie
Enrollment change, HEOR: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (clinicaltrials.gov) - Jun 24, 2013
P3, N=455, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Feb 2012 --> May 2012 N=680 --> 455
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial termination, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor (clinicaltrials.gov) - Jun 19, 2013
P4, N=96, Terminated, Sponsor: Hoffmann-La Roche
N=680 --> 455 Completed --> Terminated; The study was closed due to the slow enrollment rate.
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Anti TNF α Improves Endothelial Dysfunction in IBD Patients (clinicaltrials.gov) - Jun 17, 2013
P4, N=20, Recruiting, Sponsor: Carmel Medical Center
- ||||| Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) (clinicaltrials.gov) - Jun 16, 2013
P3, N=54, Not yet recruiting, Sponsor: Peter Higgins
Completed --> Terminated; The study was closed due to the slow enrollment rate. Initiation date: Aug 2012 --> Oct 2013
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Observational data, P4 data: Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis (clinicaltrials.gov) - Jun 13, 2013
P=N/A, N=555, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Aug 2012 --> Oct 2013 Recruiting --> Active, not recruiting
- |||||||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Jun 12, 2013
P3, N=400, Ongoing, Sponsor: Pfizer Inc.`Pfizer Inc., 235 East 42nd Street, New York, NY 10017
- Humira (adalimumab) / Eisai, AbbVie
New P2 trial: Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy (clinicaltrials.gov) - Jun 5, 2013
P2, N=0, Recruiting, Sponsor: Poitiers University Hospital
- Humira (adalimumab) / Eisai, AbbVie
Observational data, P4 data, Trial termination: A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=26, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Recruiting --> Terminated; This study was prematurely terminated due to low enrollment
- Humira (adalimumab) / Eisai, AbbVie
Observational data, P4 data, Enrollment change: A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=26, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Terminated; This study was prematurely terminated due to low enrollment N=500 --> 26
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker (clinicaltrials.gov) - Jun 4, 2013
P4, N=100, Active, not recruiting, Sponsor: University of Sao Paulo
N=500 --> 26 Recruiting --> Active, not recruiting
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
New P3 trial: SPIRIT A1: Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) (clinicaltrials.gov) - Jun 4, 2013
P3, N=0, Withdrawn, Sponsor: Eli Lilly and Company
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, PK/PD data: A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety (clinicaltrials.gov) - Jun 2, 2013
P2, N=100, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: VIP-Et: Vascular Inflammation in Psoriasis - Extension Study (clinicaltrials.gov) - May 29, 2013
P4, N=96, Recruiting, Sponsor: University of Pennsylvania
- pateclizumab (RG7416) / Roche
Enrollment change, Combination therapy: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - May 21, 2013
P2, N=211, Completed, Sponsor: Genentech
Active, not recruiting --> Completed N=210210 --> 211
- New P4 trial: Evaluation of a protocol for the reduction of doses in patients with rheumatoid arthritis (RA) in clinical remission in treatment with biological therapies Evaluaci (EUDRACT) - May 15, 2013
P4, N=28, Ongoing, Sponsor: FRANCISCO J. BLANCO GARC
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR: A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia (clinicaltrials.gov) - May 9, 2013
P=N/A, N=70, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=210210 --> 211 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
P4 data: A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) (clinicaltrials.gov) - May 5, 2013
P=N/A, N=8250, Recruiting, Sponsor: AbbVie
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical: PsoBest - The German Psoriasis Registry (clinicaltrials.gov) - May 5, 2013
P=N/A, N=3500, Recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice (clinicaltrials.gov) - Apr 7, 2013
P=N/A, N=4208, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Completed
- || Humira (adalimumab) / AbbVie
Trial completion: Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use (clinicaltrials.gov) - Apr 1, 2013
P3, N=32, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Active, not recruiting --> Completed
- HEOR: Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis (clinicaltrials.gov) - Mar 14, 2013
P=N/A, N=1000, Not yet recruiting, Sponsor: Jochen Schmitt.
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: ABILITY-3: Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis (clinicaltrials.gov) - Mar 7, 2013
P4, N=740, Recruiting, Sponsor: AbbVie
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Special Investigation in Patients With Crohn's Disease (All Patients Investigation) (clinicaltrials.gov) - Feb 28, 2013
P=N/A, N=1716, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS) (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=4500, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Humira (adalimumab) / AbbVie
Trial completion: A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA) (clinicaltrials.gov) - Feb 26, 2013
P4, N=308, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, HEOR: Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice (clinicaltrials.gov) - Feb 25, 2013
P=N/A, N=460, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: REACH: Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA (clinicaltrials.gov) - Feb 24, 2013
P=N/A, N=1000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
New P4 trial: STARA: Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 13, 2013
P4, N=400, Recruiting, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct ) (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=5914, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct ) (clinicaltrials.gov) - Feb 5, 2013
P=N/A, N=5914, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=4500 --> 5914
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population (clinicaltrials.gov) - Jan 31, 2013
P=N/A, N=60, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)